Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Thyroid : Official Journal of the American Thyroid Association|January 20, 2018
Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter StudyMijin Kim, Tae Hyuk Kim, Dong Yeob Shin, et al.
The Journal of Clinical Endocrinology and Metabolism|September 25, 2008
Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinomaWon Gu Kim, Jong Ho Yoon, Won Bae Kim, et al.
Thyroid : Official Journal of the American Thyroid Association|January 8, 2020
Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in KoreaEyun Song, Mijin Kim, Eui Young Kim, et al.
Nuclear Medicine Communications|August 19, 2011
Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinomaEui Young Kim, Tae Yong Kim, Won Gu Kim, et al.
Clinical Endocrinology|January 29, 2010
Clinical outcomes of persistent radioiodine uptake in the neck shown by diagnostic whole body scan in patients with differentiated thyroid carcinoma after initial surgery and remnant ablationEui Young Kim, Won Gu Kim, Won Bae Kim, et al.
The Journal of Clinical Endocrinology and Metabolism|January 19, 2010
Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scanWon Gu Kim, Jin-Sook Ryu, Eui Young Kim, et al.
Thyroid : Official Journal of the American Thyroid Association|April 21, 2022
Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort StudyMijin Kim, Meihua Jin, Min Ji Jeon, et al.
Thyroid : Official Journal of the American Thyroid Association|October 9, 2019
Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter StudyHye-Seon Oh, Dong Yeob Shin, Mijin Kim, et al.
Thyroid : Official Journal of the American Thyroid Association|July 12, 2012
Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatmentJi Min Han, Won Bae Kim, Ji Hye Yim, et al.
The Journal of Clinical Endocrinology and Metabolism|October 7, 2011
Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablationJi Hye Yim, Won Bae Kim, Eui Young Kim, et al.
Pageof 3